Pharmaceutical giant Eli Lilly and Co. said Monday that $64 million would be its highest offer for California biotech firm SGX Pharmaceutical. The $3 per share price was full and fair, Gino Santini, Eli Lilly senior vice president of corporate strategy and business development, said.